Markov Cohort Model
Markov Cohort Model - Related Videos
08:53
Preparation of Single-cohort Colonies and Hormone Treatment of Worker Honeybees to Analyze Physiology Associated with Role and/or Endocrine System
0 Views •
Cited by 5 •
2016
Here we describe our detailed protocol for the preparation of single-cohort honeybee colonies – a useful tool for analyzing the role-associated worker physiology. We also describe detailed protocols for treating workers with juvenile hormone and ecdysone to evaluate the involvement of these hormones in the regulation of worker behavior and/or physiology.
07:13
Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
0 Views •
Cited by 1 •
2025
This study evaluates prognostic systems for colorectal signet-ring cell carcinoma patients using machine learning models and competing risk analyses. It identifies log odds of positive lymph nodes as a superior predictor compared to pN staging, demonstrating strong predictive performance and aiding clinical decision-making through robust survival prediction tools.
06:49
A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
0 Views •
Cited by 120 •
2015
This video protocol describes a sensitive, reliable, and quick method for evaluating the neuromuscular deficits in a transgenic mouse model of amyotrophic lateral sclerosis.
12:31
In Vivo Modeling of the Morbid Human Genome using Danio rerio
0 Views •
Cited by 66 •
2013
Here, we present a systematic approach for developing physiologically relevant, sensitive and specific in vivo assays for interpreting variation in human pathology. Transient genetic manipulation via microinjection of WT and mutant human mRNA and morpholino (MO) antisense oligonucleotides harness the tractability of the developing zebrafish embryo to rapidly assay pathogenic mutations, especially, but not exclusively, in the context of human developmental disorders.
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
0 Views •
Cited by 2 •
2018
Identification of genetic variants contributing to complex human disease allows us to identify novel mechanisms. Here, we demonstrate a multiplex genotyping approach to candidate genes or gene pathway analysis that maximizes the coverage at low cost and is amenable to cohort-based studies.
FAQs
Transition probabilities determine the proportion of the cohort moving from one health state to another during each cycle. Applying these probabilities repeatedly produces estimates of disease progression, remission, complications, or death across time. Because the calculations describe population proportions, changes in the assumed probabilities can alter projected treatment outcomes and the resulting comparison between interventions.
Repeated cycles allow the model to extend outcome estimates beyond the period directly observed in clinical evidence. Each cycle updates the distribution of people across health states, so the model can represent continuing progression and accumulate consequences over time. This is particularly useful when a disease process lasts longer than the available follow-up period.
State-specific costs and utilities translate health-state occupancy into measurable economic and health outcomes. After estimating the proportion of the cohort in each state, the model assigns the corresponding cost, utility, or other outcome to those proportions. This connects disease progression with treatment evaluation, allowing interventions to be compared using consequences beyond clinical state counts alone.
The model requires defined health states, repeated time cycles, and transition probabilities describing movement among those states. It also needs the state-specific costs, utilities, or other outcomes relevant to the analysis. Together, these components establish what the cohort can experience, how its distribution changes over time, and which results will be summarized.
Researchers would use the approach when the available clinical evidence covers a shorter period than the disease process or when long-term treatment consequences must be estimated. The model projects how the observed cohort distribution may evolve through later cycles, supporting longer-term evaluation of interventions while explicitly linking those projections to defined health states and outcomes.
In medicine, analysts can use the model to compare interventions by projecting disease states and assigning associated costs, utilities, or other outcomes. These results support cost-effectiveness analysis, budget planning, and long-term treatment evaluation. The framework is therefore useful when decision-makers need population-level estimates that extend beyond the duration of direct clinical observation.